These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 31837444)
1. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444 [TBL] [Abstract][Full Text] [Related]
2. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
3. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
4. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. Jin B; Wang C; Shen Y; Pan J Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661 [TBL] [Abstract][Full Text] [Related]
5. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related]
6. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
8. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968 [TBL] [Abstract][Full Text] [Related]
9. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229 [TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096 [TBL] [Abstract][Full Text] [Related]
12. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842 [TBL] [Abstract][Full Text] [Related]
13. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Bu Q; Cui L; Li J; Du X; Zou W; Ding K; Pan J Cancer Biol Ther; 2014 Jul; 15(7):951-62. PubMed ID: 24759597 [TBL] [Abstract][Full Text] [Related]
14. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL. Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306 [TBL] [Abstract][Full Text] [Related]
15. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603 [TBL] [Abstract][Full Text] [Related]
16. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]
17. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells. Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731 [TBL] [Abstract][Full Text] [Related]
18. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201 [TBL] [Abstract][Full Text] [Related]
19. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia. Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903 [TBL] [Abstract][Full Text] [Related]
20. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation. Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]